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ABSTRACT 
A series of 1,2,3-triazole derivatives bearing different chemical entities were prepared starting from 2-(4-phenyl-
1H-1,2,3-triazol-1-yl)acetohydrazide, compound 2. The purity of all new compounds was checked by TLC and elucidation 




C NMR along with High Resolution Mass Spectrometry (HRMS). All the 
target compounds were evaluated for their possible antimicrobial activity. Most of the tested compounds showed moderate 
to good antibacterial activity against most of the bacterial strains used in comparison with ciprofloxacin as a reference 
drug. The most active compounds were 4a, 9a, 9b, and 9f. Results of antifungal activity revealed that most of the tested 
compounds showed a good antifungal activity in comparison to fluconazole as a reference drug. Compounds 4a, 9c, 9d 
and 9f were the most active ones. 
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1- INTRODUCTION 
1,2,3-Triazoles are an important class of heterocycles due to their wide range of applications as synthetic 
intermediates and pharmaceuticals [1-2]. Several therapeutically interesting 1,2,3-triazoles have been reported, 
including anti-HIV agents [3-6], antimicrobial compounds [7], ß3-selective adrenergic receptor agonists [8], kinase 
inhibitors [9-10] and other enzyme inhibitors [11-12]. The 1,2,3-triazole moiety is also present in a number of drugs, 
for example, the ß-lactam antibiotic tazobactam [13] and the cephalosporin cefatrizine [14]. 
Morbidity and mortality due to enteric bacterial infections have caused important health problems worldwide, 
mainly in the developing countries [15-16]. Toxicity and resistance to the drugs also have played an important role in 
treatment failure [17]. Consequently, there is an urgent need to screen new compounds for the development of new 
antibacterial agents. 
We report simple and efficient methods for preparation of 1,2,3-triazole derivatives bearing different chemical 
entities that promise superior antimicrobial activity. 
2- RESULTS AND DISCUSSION 
2.1. Chemistry 
The key intermediate ethyl 2-(4-phenyl-1H-1,2,3-triazol-1-yl)acetate, compound 1 was prepared according to a 
reported procedure and its structure was confirmed by matching its physical and spectral data with the reported 
one[18]. 
The novel 2-(4-phenyl-1H-1,2,3-triazol-1-yl)acetohydrazide, compound 2 was obtained through condensation of 
compound 1 with hydrazine hydrate by heating the reactants in ethanol at reflux for 6h, Scheme 1. IR spectrum of 
compound 2 showed two bands at 3290 and 3160 cm
-1
 due to NH and NH2 functions, in addition to a band at 1658 
corresponding to carbonyl group. 
1
H NMR spectrum of compound 2 showed signals derived from hydrazide structure 
appeared at 4.42 ppm (-NHNH2) and 9.57 (-NHNH2) ppm integrating for two and one protons, respectively 
(exchangeable with D2O). In addition, the spectrum also showed singlet signal at 5.10 ppm for (NCH2). HRMS of 
compound 2: Found 218.1033, Calculated for (C10H12N5O
+
) 218.1036.   
Hydrazide 2 was allowed to react with phthalic anhydride in glacial acetic acid by heating the reactants at reflux 
for 2 h to afford the new phthalimide derivative 3 in a 78% yield, Scheme 1. IR spectrum of compound 3 showed one 
band at 3260 cm
-1
 due to (–NH) stretching and two bands at 1699 and 1648 for carbonyl groups. 
1
H NMR spectrum of 
compound 3 displayed no signals belonging to –NH2 group. HRMS of compound 3: Found 348.1087, Calculated for 
(C18H14N5O3
+
) 348.1091.   
The novel thiosemicarbazide derivatives 4a-c were obtained in 76-84% yields through the reaction of acid 
hydrazide 2 with the appropriate isothiocyanate by heating the reactants at reflux in ethanol for 2 h. Furthermore, the 
thiosemicarbazides 4a-c were cyclized in hot NaOH solution as a base catalyzed reaction to obtain the novel 5-
mercapto-4-substituted-4H-1,2,4-triazole derivatives 5a-c. 
The IR spectra of compounds 4a-c showed strong absorption bands at 3265-3234 cm
-1
 and 1666-1652 cm
-1
 for 
the NH and C=O groups, respectively. In addition to a strong absorption band at 1190 cm-1 due to (C=S) group. 
Meanwhile IR spectra of compounds 5a-c displayed no bands belonging to NH and C=O groups; instead a new 
bands at 2988-2962 cm
-1
 for SH group. 
ISSN 2321-807X 
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Scheme 1 Synthesis of compounds 2, 3, 4a-c, and 5a-c 
Moreover, the novel oxadiazole 6 was synthesized in 87% yield through cyclization of the acid hydrazide 2 using 
potassium hydroxide and carbon disulfide in hot ethanolic solution. IR spectrum of compound 6 showed a band at 2961 
cm
-1
 due to SH group. HRMS of compound 6: Found 260.0594, Calculated for (C11H10N5OS
+
) 260.0601. 
The intermediate potassium 2-(2-(4-phenyl-1H-1,2,3-triazol-1-yl)acetyl)hydrazine carbodithioate 7 was prepared 
from hydrazide 2 and carbon disulfide in ethanolic potassium hydroxide solution with the aim to be cyclized to the novel 
triazole 8 under the effect of hydrazine hydrate. Structure of compound 8 was elucidated by spectral methods of analyses. 
IR spectrum of compound 8 showed two bands at 3270 and 3135 cm
-1
 due to (NH) stretching, a band at 2720 cm
-1
 for SH 
group and a strong band at 1299 cm
-1
 (C=S) stretching (thiol-thionetautomers). IR spectrum of compound 8 was devoid of 
absorption bands around 1660 cm
-1
 due to carbonyl group of hydrazide. 
1
H NMR spectrum of compound 8 displayed no 
signalsbelonging to –NH2 and –CONH groups; instead, a new singlet signal appeared at 5.68 ppm (exchangeable with 
D2O) due to –NH2 of triazole ring equivalent to two protons and a broad signal at 13.85 ppm due to exchanged –NH proton 
of triazole ring. HRMS of compound 8: Found 274.0867, Calculated for (C11H12N7S
+
) 274.0869. 
The target compounds; 9a-f were synthesized by condensation of compound 2 with (un)substituted 
benzaldehydes or acetophenone Scheme 2. The structures of compounds 9a-f were confirmed by spectral methods of 
analyses. The IR spectra of compounds 9a-f showed strong absorption bands at 3255-3160 cm
-1
 and 1680-1668 cm
-1
 for 
the NH and C=O groups, respectively.  
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Table 1. Structures and yields of compounds 2, 3, 4a-c, 5a-c, 6, 8, and 9a-f 























































































































The results of the preliminary testing of the antibacterial activity of the final compounds are given in Table II. The 
synthesized compounds 2, 3, 4a-c, 5a-c, 6, 8, and 9a-f were tested for their in vitro antibacterial activity against 
Staphylococcus aureusas a representative of Gram positive strains and Escherichia coli as a Gram negative strain using 
ciprofloxacin as a reference drug.  The result revealed that most of the newly synthesized compounds exhibited promising 
antibacterial activity comparable to ciprofloxacin against the test organisms (Table II). 
The hydrazide derivative compound 2, was found to exhibit antibacterial activity nearly 48% that of ciprofloxacin against 
Staphylococcus aureus, however it showed only 40% activity of ciprofloxacin against E.Coli. 
 According to the results in Table II, it can be noticed that conversion of hydrazide derivative, compound 2 into 
compound 3 decreased the activity against Staphylococcus aureus as it showed only 38% activity of ciprofloxacin.  
 Compounds 4a-c were found to exhibit pronounced antibacterial activity which ranged from 60-73% that of 
standard drug against Staphylococcus aureus and 45-60% that of ciprofloxacin against E.Coli. It is worthy-mentioning that 
compound 4a showed the highest activity (73%) against Staphylococcus aureus and 60% activity of ciprofloxacin against 
E.Coli.  
ISSN 2321-807X 
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Furthermore, compounds 5a-c exhibited moderate activity against Staphylococcus aureusand their activity was 
53-60% that of ciprofloxacin, but they showed weak activity (45-47% that of ciprofloxacin) against E.Coli and that 
compound 5a was the most active compound against Staphylococcus aureusas it showed 60% that of ciprofloxacin while 
it showed only 47% activity against E.Coli. It was noticed that cyclization of thiosemicarbazides 4a-c to their corresponding 
triazole derivatives 5a-c led to decrease of the antibacterial activity. 
The oxadiazole derivative, compound 6 showed moderate activity against Staphylococcus aureusand its activity 
was 68% that of ciprofloxacin while it showed only 55% activity of ciprofloxacin against E.Coli. Meanwhile, the conversion 
of hydrazide 2 into the amino triazole derivative, compound 8 did not show a significant improvement in the antibacterial 
characters of compound 2.  
 Compounds 9a-f were found to exhibit pronounced antibacterial activity which ranged from 65-85% that of 
standard drug against Staphylococcus aureus and 50-80% that of ciprofloxacin against E.Coli. It is worthy-mentioning that 
compound 9f showed the highestactivity (85%) against Staphylococcus aureus while compound 9d was the most active 
derivative against E.Coli(80% avtivity).  
 
Table II. Inhibitory zone diameter (mm) of compounds 2, 3, 4a-c, 5a-c, 6, 8, and 9a-f 






2 19 16 16 
3 15 16 16 
4a 29 24 28 
4b 25 21 25 
4c 24 18 26 
5a 24 19 21 
5b 20 18 22 
5c 21 18 20 
6 27 22 24 
8 20 21 18 
9a 28 20 26 
9b 28 24 24 
9c 26 20 30 
9d 26 32 30 
9e 26 24 32 
9f 34 26 30 
Ciprofloxacin 40 40 -- 
Fluconazole -- -- 40 
 
All the synthesized compounds 2, 3, 4a-c, 5a-c, 6, 8, and 9a-f were tested as potential antifungal agents against Candida 
albicans using Fluconazole as a reference drug (Table II). 
 The results revealed that the tested compounds showed a varying degree of antifungal activity against the test organism. 
Compound 2 showed activity 40% that of fluconazole. Moreover, further derivatization of compound 2 with different 
(un)substituted benzaldehydes and acetophenone, compounds 9a-f affords compounds with improved antifungal activity 
against Candida albicans, showing activity 50-80% that of fluconazole. Compound 9e displayed the higher antifungal 
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3 CONCLUSION 
In conclusion, several 1,2,3-triazole derivatives bearing different chemical entities were synthesized. A microbiological 
study was undertaken to evaluate the effect of the synthesized compounds on different bacterial and fungal strains. The 
results of the preliminary testing of the antibacterial activity of the final compounds revealed that the majority of the 
synthesized compounds show varying degrees of inhibition against the tested microorganisms. In general, the inhibitory 
activity against the Gram-positive bacteria was higher than against the Gram-negative bacteria. The triazole derivatives 
4a, 9a, 9b, and 9f, displayed the highest activity. Results of antifungal activity revealed that all compounds showed a weak 
to a good antifungal activity and that compounds 9c, 9d, 9e and 9f were the most active ones. 
4 EXPERIMENTAL 
4.1. Chemistry 
Reagents used for synthesis were purchased from Sigma-Aldrich (Gillingham – Dorest, UK) and MERCK (Schuchardt, 
Germany). All solvents were obtained from commercial suppliers and used without further purification. The starting 
material ethyl 2-(4-phenyl-1H-1,2,3-triazol-1-yl)acetate, compound 1[18] was prepared according to reportedprocedure. 
Melting points were determined on an electro thermal melting point apparatus [Stuart Scientific, model SMP3, England, 
UK], and were uncorrected. Pre-coated silica gel plates (kieselgel 0.25 mm, 60G F254, Merck, Germany) were used for 
TLC monitoring of reactions. The developing solvent systems of CHCl3/CH3OH (9.5:0.5 V/V) were used and the spots 
were detected at 254 nm wavelength using ultraviolet lamp (Spectroline, model CM-10, USA). The target compounds were 
crystallized from ethanol unless otherwise specified. IR spectra (KBr discs) were recorded on a shimadzu IR-470 
spectrometer (Shimadzu, Kyoto, Japan) at Faculty of Pharmacy, Assiut University, Assiut. NMR Spectra were taken using 
a Varian Unity INOVA 400 MHz and Bruker AC250 MHz spectrometers for proton and carbon. All numbers referring to 
NMR data obtainedare in parts per million (ppm) relative to TMS as an internal standard, using DMSO-d6, unless 
otherwise specified, as a solvent, and deuterium oxide was used for the detection of exchangeable protons.. High 
resolution mass spectrometric data were obtained using the EPSRC mass spectrometry centre in Swansea and Thermo 
Instruments MS system (LTQ XL/LTQ Orbitrap Discovery) coupled to a Thermo Instruments HPLC system (Accela PDA 
detector, Accela PDA autosampler and Pump) at university of Aberdeen. 
Synthesis of 2-(4-phenyl-1H-1,2,3-triazol-1-yl)acetohydrazide (2) 
To a solution of ethyl 2-(4-phenyl-1H-1,2,3-triazol-1-yl)acetate, compound 1(3.17 g, 0.013 mol) in absolute 
ethanol (40 mL), hydrazine hydrate 99% (1.00 g, 0.02 mole) was added. The reaction mixture was refluxed for 6 h, and 
then cooled. The precipitated product was filtered, washed with cold ethanol, dried, and crystallized from ethanol as white 
crystals. 
Synthesis of N-(1,3-dioxoisoindolin-2-yl)-2-(4-phenyl-1H-1,2,3-triazol-1-yl)acetamide (3) 
A mixture of the hydrazide 1 (0.001 mol) and phthalic anhydride (0.001 mol) in glacial acetic acid (10 mL) was 
heated at reflux for 2 h, after cooling, the separated product was filtered and crystallized from DMF/H2O. 
General procedure for preparation of N-alkyl/aryl-2-(2-(4-phenyl-1H-1,2,3-triazol-1-
yl)acetyl)hydrazine carbothioamide (4a-c) 
A mixture of the hydrazide 2 (0.002 mol) and the appropriate isothiocyanate (0.002 mol) in ethanol (10 mL) was 
heated at reflux for 2 h, after cooling, the separated product was filtered and crystallized from ethanol. 
General procedure for preparation of 4-alkyl/aryl-5-((2-(4-phenyl-1H-1,2,3-triazol-1-yl)methyl)-
4H-1,2,4-triazole-3-thiol (5a-c) 
Compounds 4a-c (0.002 mol) were dissolved in NaOH (2N, 10 mL), then heated under reflux for 2 h. The solution 
was cooled, filtered and then acidified with HCl (2N). The separated solid was filtered and crystallized from DMF/H2O. 
Synthesis of 5-((4-phenyl-1H-1,2,3-triazol-1-yl)methyl)-1,3,4-oxadiazole-2-thiol (6) 
The acid hydrazide 2 (0.002 mol) was stirred in ethanol (20 mL) containing potassium hydroxide (0.002 mol) for 1 
h until a clear solution was obtained. Carbon disulfide (0.005 mol) was added dropwise to the stirred reaction mixture, and 
then it was heated under reflux for 6 h. The reaction mixture was concentrated, cooled, and acidified with diluted HCl. The 
separated product was filtered, washed with water, and crystallized from ethanol. 
Synthesis of potassium 2-(2-(4-phenyl-1H-1,2,3-triazol-1-yl)acetyl)hydrazinecarbodithioate (7) 
Carbon disulfide (0.015 mol) was added dropwise to an ice-cooled solution of ethanol (20 mL) containing KOH 
(0.01 mol) and hydrazide 2 (0.01 mol). The mixture was stirred for 14 h, and then dry diethyl ether (10 mL) was added. 
The separated solid was filtered and then washed twice with diethyl ether (20 mL). The obtained product was used in the 
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Synthesis of 4-amino-5-((4-phenyl-1H-1,2,3-triazol-1-yl)methyl)-4H-1,2,4-triazole-3-thiol (8) 
A mixture of intermediate 7 (0.005 mol) and hydrazine hydrate (99%; 0.01 mol) in ethanol (20 mL) was refluxed 
for 4 h. the reaction mixture was diluted with cold water, then neutralized by portion wise addition of concentrated HCl. The 
formed precipitate was filtered, washed with water, and crystallized from ethanol. 
General procedure for preparation of N-arylidene-2-(4-phenyl-1H-1,2,3-triazol-1-yl)aceto- 
hydrazide (9a-f) 
To a suspension of hydrazide2(0.002 mol) in ethanol (10 mL) and the appropriate aryl aldehyde (0.002 mol), 2 
drops of glacial acetic acid were added, and then the reaction mixture was heated under reflux for 4-6 h. The reaction 
mixture was cooled and the precipitated product was filtered, washed with cold ether and crystallized from ethanol. 
Spectral Data of New Compounds 
2-(4-phenyl-1H-1,2,3-triazol-1-yl)acetohydrazide(2). Yield (82%), mp 186-188 
o
C; IR spectrum (v/cm
-1
): 3290, 
3160 (NH); 1658 (C=O); 1620, 1584, 1530, 1485, 1460 (C=N/C=C); 
1
H NMR spectrum (DMSO-d6): δ (ppm): 9.57 (s, 
1H); 8.54 (s, 1H); 7.91-7.84 (m, 2H); 7.45 (t, J = 7.6 Hz, 2H); 738-7.28 (m, 1H); 5.10 (s, 2H); 4.42 (s, 2H); 
13
C NMR 
spectrum (DMSO-d6): δ (ppm): 164.79; 146.21; 130.72; 128.94; 127.88; 125.17; 122.82; 50.70; HRMS calcd for 
C10H11N5O [M+H]
+
 218.1036 Found 218.1033. 





): 3260 (NH); 1699; 1648 (C=O); 1610; 1594; 1520; 1487; 1460 (C=N/C=C); 
1
H NMR spectrum 
(DMSO-d6): δ (ppm): 8.62 (d, J = 1.0 Hz, 1H); 8.01-7.83 (m, 6H); 7.45 (t, J = 7.7 Hz, 2H); 7.34 (td, J = 7.2 Hz, 1.3 Hz, 
1H); 5.56 (s, 2H); 
13
C NMR spectrum (DMSO-d6): δ (ppm): 165.33; 164.76; 146.32; 135.33; 130.55; 129.40; 128.94; 
127.94; 125.18; 123.83; 123.11; 50.09; HRMS calcd for C18H13N5O3 [M+H]
+
348.1091 Found 348.1087. 
N-phenyl-2-(2-(4-phenyl-1H-1,2,3-triazol-1-yl)acetyl)hydrazinecarbothioamide (4a). Yield (84%), mp 198-200 
o
C; IR spectrum (v/cm
-1
): 3265 (NH); 1658 (C=O); 1610; 1590; 1527; 1482; 1460 (C=N/C=C); 1191 (C=S); 
1
H NMR 
spectrum (DMSO-d6): δ (ppm): 10.56 (s, 1H); 9.79 (d, J = 9.6 Hz, 2H); 8.56 (s, 1H); 7.88 (d, J = 7.6 Hz, 2H); 7.50-
7.30 (m, 7H); 7.20 (t, J = 7.3 Hz, 1H); 5.29 (s, 2H); 
13
C NMR spectrum (DMSO-d6): δ (ppm): 146.25; 138.97; 130.65; 
128.95; 128.19; 127.91; 125.17; 122.97;  50.68; HRMS calcd for C17H16N6O5 [M+H]
+
 353.1179 Found 353.1178. 
N-ethyl-2-(2-(4-phenyl-1H-1,2,3-triazol-1-yl)acetyl)hydrazinecarbothioamide(4b). Yield (76%), mp 224-226 
o
C; IR spectrum (v/cm
-1
): 3245 (NH); 1666 (C=O); 1610; 1590; 1527; 1482; 1460 (C=N/C=C); 1192 (C=S); 
1
H NMR 
spectrum (DMSO-d6): δ (ppm): 10.31 (s, 1H); 9.34 (s, 1H); 8.54 (s, 1H); 8.16 (t, J = 5.6 Hz, 1H); 7.87 (d, J = 7.6 Hz, 
2H); 7.45 (t, J = 7.6 Hz, 2H); 7.34 (t, J = 7.4 Hz, 1H); 5.23 (s, 2H); 3.49 (p, J = 6.9 Hz, 2H); 1.09 (t, J = 7.1 Hz, 3H); 
13
C NMR spectrum (DMSO-d6): δ (ppm): 169.40; 165.40; 146.27; 130.65; 128.95; 127.92; 125.17; 122.92; 50.64; 
38.53; 14.50; HRMS calcd for C13H16N6O5 [M+H]
+
 305.1179 Found 305.1177. 





): 3234 (NH); 1652 (C=O); 1590; 1587; 1532; 1480; 1467 (C=N/C=C); 1191 (C=S); 
1
H NMR 
spectrum (DMSO-d6): δ (ppm): 10.36 (s, 1H); 9.47 (s, 1H); 8.53 (s, 1H); 8.36 (t, J = 5.6 Hz, 1H); 7.91-7.84 (m, 2H); 
7.45 (t, J = 7.6 Hz, 2H); 7.38-7.29 (m, 1H); 5.84 (ddt, J = 17.3, 10.2, 5.1 Hz, 1H); 5.25 (s, 2H); 5.19-5.03 (m, 2H); 4.14 
(t, J = 5.4 Hz, 2H); 
13
C NMR spectrum (DMSO-d6): δ (ppm): 165.47; 146.26; 134.80; 130.66; 128.95; 127.92; 125.17; 
122.90; 115.32; 50.66; 45.90; HRMS calcd for C14H16N6O5 [M+H]
+
 317.1179 Found 317.1177. 





): 2988 (SH); 1590; 1527; 1482; 1460 (C=N/C=C); 
1
H NMR spectrum (DMSO-d6): δ (ppm): 8.26 
(s, 1H); 7.75 (d, J = 7.7 Hz, 2H); 7.51-7.38 (m, 5H); 7.37-7.28 (m, 3H); 5.26 (s, 2H); 
13
C NMR spectrum (DMSO-d6): δ 
(ppm): 168.71; 146.90; 146.34; 132.78; 130.32; 129.64; 129.39; 128.88; 127.98; 127.89; 125.19; 122.07; 44.53; 
HRMS calcd for C17H14N6S [M+H]
+
 335.1073 Found 335.1071. 





): 3245 (NH); 2962 (SH); 1580; 1532; 1482; 1460 (C=N/C=C); 
1
H NMR spectrum (DMSO-d6): δ 
(ppm): 13.93 (s, 1H); 8.70 (s, 1H); 7.88 (d, J = 7.5 Hz, 2H); 7.44 (t, J = 7.6 Hz, 2H); 7.33 (t, J = 7.4 Hz, 1H); 5.94 (s, 
2H); 4.04 (q, J = 7.1 Hz, 2H); 1.02 (t, J = 7.1 Hz, 3H); 
13
C NMR spectrum (DMSO-d6): δ (ppm): 167.23; 146.97; 









): 2971 (SH); 1591; 1530; 1482; 1457 (C=N/C=C); 
1
H NMR spectrum (DMSO-d6): δ (ppm): 14.00 
(s, 1H); 8.65 (s, 1H); 7.90-7.82 (m, 2H); 7.49-7.40 (m, 2H); 7.38-7.28 (m, 1H); 5.85 (s, 2H); 5.73 (ddt, J = 17.3, 10.6, 
5.2 Hz, 1H); 5.03 (dq, J = 10.3, 1.4 Hz, 1H); 4.93 (dt, J = 17.1, 1.4 Hz, 1H); 4.69 (dt, J = 5.2, 1.7 Hz, 1H); 
13
C NMR 
spectrum (DMSO-d6): δ (ppm): 167.76; 147.05; 146.81; 130.65;  130.37; 128.92; 128.06; 125.26; 125.25; 122.29; 
117.44; 45.24; 44.15; HRMS calcd for C14H14N6S [M+H]
+
 299.1073 Found 299.1072. 





): 2961 (SH); 1601; 1537; 1482; 1457 (C=N/C=C); 
1
H NMR spectrum (DMSO-d6): δ (ppm): 8.72 (d, J 
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spectrum (DMSO-d6): δ (ppm): 178.19; 158.23; 146.98; 130.23; 129.00; 128.23; 125.38; 122.46; 44.17; HRMS calcd 
for C11H9N5OS [M+H]
+
 260.0601 Found 260.0594. 





): 3270; 3135 (NH2 and NH); 2720 (SH); 1615; 1560; 1485; 1461 (C=N/C=C); 1299 (C=S); 
1
H 
NMR spectrum (DMSO-d6): δ (ppm): 13.85 (s, 1H); 8.73 (d, J = 0.7 Hz, 1H); 8.62 (d, J = 0.7 Hz, 1H); 7.91-7.83 (m, 
3H); 7.51-7.40 (m, 3H); 7.40-7.29 (m, 1H); 5.94 (s, 1H); 5.76 (s, 2H); 5.68 (s, 2H); 
13
C NMR spectrum (DMSO-d6): δ 
(ppm): 178.06; 167.21; 158.22; 147.25; 146.83; 146.58 130.47; 130.20; 128.89; 128.89; 128.18; 128.00; 125.28; 
125.24; 122.44; 122.16; 44.04; 43.56; HRMS calcd for C11H11N7S [M+H]
+
 274.0869 Found 274.0867. 





): 3185 (NH); 1673 (C=O); 1608; 1583; 1483; 1458 (C=N/C=C); 
1
H NMR spectrum (DMSO-d6): δ 
(ppm): 11.90 (s, 1H); 8.56 (s, 1H); 8.08 (s, 1H); 7.92-7.83 (m, 2H); 7.80-7.73 (m, 2H); 7.51-7.41 (m, 5H); 7.39-7.30 
(m, 1H); 5.76 (s, 2H); 
13
C NMR spectrum (DMSO-d6): δ (ppm): 167.38; 146.14; 144.57; 133.84; 130.80; 130.16; 




(E)-N-(4-chlorobenzylidene)-2-(4-phenyl-1H-1,2,3-triazol-1-yl) acetohydrazide (9b). Yield (85%), mp 198-199 
o
C; IR spectrum (v/cm
-1
): 3160 (NH); 1668 (C=O); 1610; 1578; 1488; 1461 (C=N/C=C); 
1
H NMR spectrum (DMSO-
d6): δ (ppm): 11.96 (s, 1H); 8.56 (s, 1H); 8.06 (s, 1H); 7.87 (d, J = 7.5 Hz, 2H); 7.83-7.73 (m, 2H); 7.56-7.42 (m, 4H); 
7.39-7.30 (m, 1H); 5.76 (s, 2H); 
13
C NMR spectrum (DMSO-d6): δ (ppm): 167.47; 162.21; 146.67; 146.27; 146.15; 
143.27; 134.79; 134.59; 132.86; 130.79; 130.67; 128.94; 128.90; 128.88; 128.73; 127.89; 127.82; 125.16; 125.11; 
123.18; 122.89; 51.15; 50.70; HRMS calcd for C17H14 ClN5O [M+H]
+
 340.0960 Found 340.0962. 
(E)-N-(4-bromobenzylidene)-2-(4-phenyl-1H-1,2,3-triazol-1-yl)acetohydrazide  (9c). Yield (87%), mp 201-203 
o
C; IR spectrum (v/cm
-1
): 3165 (NH); 1680 (C=O); 1609; 1580; 1483; 1461 (C=N/C=C); 
1
H NMR spectrum (DMSO-
d6): δ (ppm): 11.96 (s, 1H); 8.55 (s, 1H); 8.05 (s, 1H); 7.91-7.83 (m, 2H); 7.76-7.69 (m, 2H); 7.69-7.61 (m, 3H); 7.51-
7.42 (m, 2H); 7.39-7.30 (m, 1H); 5.76 (s, 2H); 
13
C NMR spectrum (DMSO-d6): δ (ppm): 167.48; 146.15; 143.18; 
133.14; 131.86; 131.82; 130.78; 129.10; 128.96; 128.94; 127.83; 125.16; 125.11; 123.40; 123.18; 50.70; HRMS calcd 
for C17H14BrN5O[M+H]
+
384.0454 Found 384.0455. 
(E)-N-(4-fluorobenzylidene)-2-(4-phenyl-1H-1,2,3-triazol-1-yl)acetohydrazide (9d). Yield (84%), mp 199-200 
o
C; IR spectrum (v/cm
-1
): 3175 (NH); 1677 (C=O); 1606; 1581; 1486; 1462 (C=N/C=C); 
1
H NMR spectrum (DMSO-
d6): δ (ppm): 11.90 (s, 1H); 8.56 (d, J = 2.5 Hz, 1H); 8.07 (d, J = 2.5 Hz, 1H); 7.92-7.75 (m, 5H); 7.46 (td, J = 7.7, 2.6 
Hz, 3H); 7.39-7.25 (m, 1H); 5.75 (d, J = 2.2 Hz, 1H); 5.30 (d, J = 2.0 Hz, 1H); 
13
C NMR spectrum (DMSO-d6): δ 
(ppm): 167.39; 146.13; 143.40; 130.79; 130.50; 129.33; 129.25; 128.94; 127.82; 125.15; 125.10; 123.18; 116.00; 
115.78; 50.70; HRMS calcd for C17H14 FN5O [M+H]
+
 324.1255 Found 324.1252. 
(E)-N-(4-(dimethylamino)benzylidene)-2-(4-phenyl-1H-1,2,3-triazol-1-yl)aceto- hydrazide (9e). Yield (78%), 
mp 192-194 
o
C; IR spectrum (v/cm
-1
): 3255 (NH); 1677 (C=O); 1613; 1576; 1487; 1461 (C=N/C=C); 
1
H NMR 
spectrum (DMSO-d6): δ (ppm): 11.58 (d, J = 2.9 Hz, 1H); 8.58-8.52 (m, 1H); 7.96-7.82 (m, 3H); 7.60-7.41 (m, 4H); 
7.35 (ddd, J = 8.9, 5.3, 3.2 Hz, 1H); 6.74 (dt, J = 9.0, 2.0 Hz, 2H); 5.69 (d, J = 3.2 Hz, 2H); 3.07-2.84 (m, 6H); 
13
C 
NMR spectrum (DMSO-d6): δ (ppm): 166.66; 151.52; 146.09; 145.37; 130.83; 128.93; 128.60; 128.35; 127.79; 
125.14; 125.10; 123.21; 121.13; 111.76; 50.65; 39.77; 30.70; HRMS calcd for C19H20N6O [M+H]
+
 349.1771 Found 
349.1765. 





): 3165 (NH); 1673 (C=O); 1610; 1576; 1487; 1461 (C=N/C=C); 
1
H NMR spectrum (DMSO-d6): δ 
(ppm): 11.12 (s, 1H); 8.57 (s, 1H); 7.94-7.84 (m, 5H); 7.50-7.40 (m, 4H); 7.37-7.32 (m, 1H); 5.80 (s, 2H); 2.31 (s, 3H); 
13
C NMR spectrum (DMSO-d6): δ (ppm): 168.31; 149.28; 146.16; 137.83; 130.85; 129.33; 128.94; 128.41; 127.81; 
126.29; 125.13; 123.20; 51.23; 13.80; HRMS calcd for C18H17N5O [M+H]
+
320.1506 Found 320.1503. 
4.2. Biology 
4.2.1. Antibacterial screening Organisms and culture conditions 
The used bacterial cultures were obtained from Assiut University Mycological Center (AUMC), Assiut University. The 
synthesized compounds (2, 3, 4a-c, 5a-c, 6, 8, and 9a-f) were tested for their in-vitro antibacterial activity in comparison to 
ciprofloxacin as a reference drug using the standard agar cup diffusion method[19] against Staphylococcus aureus(AUMC 
B54) as a representative of Gram positive strains, while the Gram negative strains were represented by Escherichia coli 
(AUMC B69). 
Materials and method 
Bacterial strains were individually cultured for 48 h in 100 mL conical flasks containing 30 mL Nutrient Agar (NA). Assay 
was done in 10 cm sterile Petri dishes in which one mL bacterial suspension and 15 mL of NA were poured. Plates were 
shaken gently to homogenize the inocula. After solidification of the media, 5 mm cavities were cut in the solidified agar (4 
cavities/plate) using sterile cork borer. The test compounds (2, 3, 4a-c, 5a-c, 6, 8, and 9a-f) and ciprofloxacin were 
dissolved in dimethyl sulfoxide (100 μmol/mL) and were pipeted in the cavities. In addition, other cavities were pipeted 
with the solvent (DMSO) and served as a negative control. The seeded plates were incubated at 28 ± 2°C for 48 h. 
The radii of inhibition zones (in mm) of triplicate sets were measured and the results are cited in table II. 
ISSN 2321-807X 
3484 | P a g e                                                   J a n u a r y  1 7 ,  2 0 1 5  
4.2.2. Antifungal screening Organisms and culture conditions 
The used Sabouraud Agar (SA) media were prepared in Assiut University Mycological Center (AUMC), Assiut University. 
The test compounds (2, 3, 4a-c, 5a-c, 6, 8, and 9a-f) were evaluated for their antifungal activity in-vitro, in comparison to 
fluconazole as a reference drug using the standard agar cup diffusion method[20] against a pathogenic fungal species 
Candida albicans (Robin) Berkhout (AUMC 418). 
Materials and method 
Spore suspension in sterile distilled water was prepared from 7 days old culture of the test fungi growing on Sabouraud's 
dextrose broth (30 mL) media in 100 mL conical flasks. The final spore concentration was nearly 5×104 spores/mL. About 
15 mL of the growth medium was introduced on sterilized Petri dishes of 10 cm diameter and inoculated with 1 mL of 
spore suspension. Plates were shaken gently to homogenize the inocula. After solidification of the media, 5 mm cavities 
were cut in the solidified agar (4 cavities/plate) using sterile cork borer and was filled with the solutions of the test 
compounds (2, 3, 4a-c, 5a-c, 6, 8, and 9a-f) and fluconazole (100 μmol/mL in DMSO). In addition, other cavities were 
impregnated with the solvent (DMSO) and served as a negative control. The seeded plates were incubated at 28±2°C for 
7 days. The radii of inhibition zones (in mm) of triplicate sets were measured at successive intervals during the incubation 
period and the results are displayed in table II. 
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